MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells

Combination therapy of erlotinib plus bevacizumab improves progression-free survival of patients with epidermal growth factor receptor–mutated (EGFR-mutated) advanced non–small-cell lung cancer (NSCLC) compared with erlotinib alone. Although improved delivery and distribution of erlotinib to tumours...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishidate, Masanobu, Yamamoto, Kaname, Masuda, Chinami, Aikawa, Hiroaki, Hayashi, Mitsuhiro, Kawanishi, Takehiko, Hamada, Akinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711937/
https://www.ncbi.nlm.nih.gov/pubmed/29196706
http://dx.doi.org/10.1038/s41598-017-17211-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711937/
https://www.ncbi.nlm.nih.gov/pubmed/29196706
http://dx.doi.org/10.1038/s41598-017-17211-6

Ejemplares similares